GOLDENWELL BIOTECH, INC. (GWLL)
Q3-CY2026Q2-CY2026Q1-CY2026Q4-CY2025Q3-CY2025Q2-CY2025Q1-CY2025Q4-CY2024Q3-CY2024Q2-CY2024Q1-CY2024Q4-CY2023Q3-CY2023Q2-CY2023Q1-CY2023Q4-CY2022Q3-CY2022Q2-CY2022Q1-CY2022Q4-CY2021Q3-CY2021Q2-CY2021Q1-CY2021Q4-CY2020Q3-CY2020Q2-CY2020Q1-CY2020Q4-CY2019Q3-CY2019Q2-CY2019Q1-CY2019Q4-CY2018Q3-CY2018Q2-CY2018Q1-CY2018Q4-CY2017Q3-CY2017Q2-CY2017Q1-CY2017Q4-CY2016Q3-CY2016Q2-CY2016Q1-CY2016Q4-CY2015Q3-CY2015Q2-CY2015Q1-CY2015Q4-CY2014Q3-CY2014
Balance Sheet Date2026-Mar-312025-Dec-312025-Sep-302025-Jun-302025-Mar-312024-Dec-312024-Sep-302024-Jun-302024-Mar-312023-Dec-312023-Sep-302023-Jun-302023-Mar-312022-Dec-312022-Sep-302022-Jun-302022-Mar-312021-Dec-312021-Sep-302021-Jun-302021-Mar-312020-Dec-312020-Sep-30
Fiscal PeriodQ1-FY2026Q4-FY2025Q3-FY2025Q2-FY2025Q1-FY2025Q4-FY2024Q3-FY2024Q2-FY2024Q1-FY2024Q4-FY2023Q3-FY2023Q2-FY2023Q1-FY2023Q4-FY2022Q3-FY2022Q2-FY2022Q1-FY2022Q4-FY2021Q3-FY2021Q2-FY2021Q1-FY2021Q4-FY2020Q3-FY2020
Operating Cash Flow(13,361$)(18,848$)(30,885$)59,380$(32,276$)(25,351$)(20,965$)(47,751$)(29,010$)(19,076$)(35,210$)(26,946$)(31,921$)(917,090$)15,222$(25,037$)(145,655$)(19,373$)(12,506$)(150,201$)(150,200$)(2,975$)(142$)(2,329$)(2,311$)
Investing Cash Flow
Purchases of Property and Equipment
Financing Cash Flow0$0$0$0$0$70,000$0$49,250$0$60,388$30,000$0$30,000$0$0$170,125$170,125$170,125$1,000$0$7,300$248,904$
End Cash Position13,414$26,775$45,622$76,507$17,127$49,404$4,755$25,720$24,221$53,231$11,920$17,130$44,075$45,996$58,086$42,864$67,901$213,556$232,929$245,435$248,569$248,569$250,544$251,422$251,564$246,593$0$
Exchange Rate Effect
Dividends Paid
Unlevered Free Cash Flow(13,361$)(18,848$)(30,885$)59,380$(32,276$)(25,351$)(20,965$)(47,751$)(29,010$)(19,076$)(35,210$)(26,946$)(31,921$)(917,090$)15,222$(25,037$)(145,655$)(19,373$)(12,506$)(150,201$)(150,200$)(2,975$)(142$)(2,329$)(2,311$)